Fermenta Biotech

Fermenta Biotech Book Value Growth

The Book Value Growth of Fermenta Biotech (506414.BO) as of Oct 22, 2026 is 25.55 %. In the previous year, Book Value Growth was -8.19 % — a change of -411.93% (higher).

Book Value Growth

25.55 %

YoY

-411.93%

Last updated:

Book Value Growth of Fermenta Biotech is 2025 25.55 % . Book Value Growth of Fermenta Biotech was 2024 -8.19 % . It decreases by -411.93% higher compared to the previous year.

The Fermenta Biotech Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2018
-11.72 INR
Jan 1, 2019
101.33 INR
Jan 1, 2020
23.50 INR
Jan 1, 2021
16.53 INR
Jan 1, 2022
3.20 INR
Jan 1, 2023
-15.45 INR
Jan 1, 2024
-8.19 INR
Jan 1, 2025
25.55 INR
The Fermenta Biotech Book Value Growth history
YEARBook Value GrowthYoY
25.55 %-411.93%
-8.19 %-46.98%
-15.45 %-582.62%
3.20 %-80.63%
16.53 %-29.66%
23.50 %-76.80%
101.33 %-964.21%
-11.72 %-236.42%
8.59 %-727.80%
-1.37 %+69.33%
-0.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fermenta Biotech Stock analysis

What does Fermenta Biotech do? Fermenta Biotech Ltd manufactures and supplies Vitamin D3, operating through its Chemicals/Bulk Drug segment that produces bulk drugs and enzymes for pharmaceuticals, dietary supplements, food fortification, animal feed, veterinary, and rodenticide industries. The Property segment generates revenue by renting and selling properties. The company's proprietary enzyme portfolio supports biopharmaceutical product development, while its nutritional ingredients include fish oil-derived cholesterol for aquaculture, natural astaxanthin, and vitamin AD2 premix, all sold to customers in the specified sectors. The Chemicals/Bulk Drug segment serves pharmaceutical, dietary supplement, food and beverage, animal feed, veterinary, and rodenticide markets with bulk drugs and enzymes. The Property segment focuses on real estate transactions, providing rental and sales services for its properties. Fermenta Biotech's product portfolio targets industries requiring specialized biopharmaceutical technologies and nutritional supplements, with key offerings like Vitamin D3, fish oil cholesterol, astaxanthin, and vitamin AD2 premix directly sold to these sectors. Fermenta Biotech Ltd's revenue streams come from the sale of Vitamin D3 and other bulk drugs through its Chemicals/Bulk Drug segment, while the Property segment contributes through property rentals and sales. The company's nutritional ingredients, such as fish oil-derived cholesterol, natural astaxanthin, and vitamin AD2 premix, are sold to industries including pharmaceuticals, dietary supplements, food fortification, animal feed, and veterinary sectors, with no additional brand or customer details provided beyond the business description. Fermenta Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fermenta Biotech stock

Book Value Growth of Fermenta Biotech is 25.55 % in 2025.

On Eulerpool you can find the complete historical development of Book Value Growth Fermenta Biotech since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Fermenta Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Fermenta Biotech

All Key Metrics — Fermenta Biotech